<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047890</url>
  </required_header>
  <id_info>
    <org_study_id>15200</org_study_id>
    <nct_id>NCT02047890</nct_id>
  </id_info>
  <brief_title>Japanese BAY1000394 Monotherapy Phase I Study</brief_title>
  <official_title>An Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Japanese Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized, dose-escalating Phase I study to evaluate the safety,
      tolerability, pharmacokinetics of BAY1000394 given in a 3 days on / 4 days off schedule in
      Japanese subjects with advanced malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 19, 2014</start_date>
  <completion_date type="Actual">July 19, 2018</completion_date>
  <primary_completion_date type="Actual">January 6, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal lab parameters based on descriptive statistics</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed drug concentration (Cmax) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax divided by dose per body weight (Cmax,norm) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax divided by dose (Cmax/D) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration versus time curve from zero to infinity after single dose (AUC) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>= Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to 12 hours after single dose (AUC(0-12) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8 and 12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC divided by dose per body weight (AUCnorm) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCnorm from time 0 to 12 hours after single dose (AUC(0-12),norm) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8 and 12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC divided by dose (AUC/D) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (tmax) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t½) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed drug concentration after multiple dosing (Cmax,md) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax divided by dose per body weight after multiple dosing (Cmax,norm,md) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax divided by dose (Cmax,md/D) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to 12 hours after multiple dosing (AUC(0-12),md) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCnorm from time 0 to 12 hours after multiple dosing (AUC(0-12),norm,md) for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to 12 hours divided by dose after multiple dosing for BAY1000394 and its metabolite M-1</measure>
    <time_frame>Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Screening and on Day 21 of even numbered cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BAY1000394</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 12 subjects will be included: 3 to 6 evaluable subjects for each cohort. The cycle length will be 3 weeks (21 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1000394 (2.5mg)</intervention_name>
    <description>BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)</description>
    <arm_group_label>BAY1000394</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1000394 (5mg)</intervention_name>
    <description>BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)</description>
    <arm_group_label>BAY1000394</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese male or female subjects aged ≥20 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1

          -  Life expectancy of at least 12 weeks

          -  Subjects with advanced, histologically or cytologically confirmed solid tumors, not
             amenable to any standard therapy, have no standard therapy available, or subjects must
             have actively refused any treatment which would be regarded standard, and if in the
             judgment of the investigator, experimental treatment is clinically and ethically
             acceptable

          -  At least 1 tumor lesion evaluable by computer tomography (CT) or scan or magnetic
             resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors
             (RECIST) version 1.1

          -  Adequate bone marrow, liver, and renal functions

        Exclusion Criteria:

          -  Anticancer chemotherapy or immunotherapy within 4 weeks of study entry. Mitomycin C or
             nitrosoureas should not be given within 6 weeks of study entry.

          -  Radiotherapy to target lesions within 3 weeks prior to the first dose of study drug.

          -  Use of biological response modifiers, such as granulocyte colony-stimulating factor
             (G-CSF), within 3 weeks prior to the first dose of study drug.

          -  Symptomatic metastatic brain or meningeal tumors.

          -  Investigational drug treatment outside of this study during or within 4 weeks prior to
             study entry.

          -  Blood pressure &lt;100/60 mmHg or pulse &gt;100 BPM
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 27, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>June 20, 2019</last_update_submitted>
  <last_update_submitted_qc>June 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDK inhibitor</keyword>
  <keyword>BAY1000394</keyword>
  <keyword>Advanced malignancies</keyword>
  <keyword>Japanese</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

